Gαs Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer

Table 6

Univariate and Multivariate analysis of clinical factors in relation to PSA progression-free survival.

	Univariate HR (95%)	𝑃	Multivariate HR (95%)	𝑃
Negative Gαs	5.269 (1.187–7.589)	<0.001*	4.328 (1.876–8.432)	<0.001*
Age at diagnosis	1.132 (0.809–1.727)	0.413	0.743 (0.239–3.158)	0.712
Clinical stage at diagnosis	2.787 (1.131–4.238)	<0.001*	2.135 (0.897–5.328)	0.117
Gleason score at diagnosis	5.821 (3.496–10.825)	<0.001*	3.219 (1.276–8.557)	<0.001
Preoperative PSA	1.784 (1.389–3.476)	<0.001*	0.976 (0.597–2.911)	0.061
Angiolymphatic invasion	1.829 (1.142–2.109)	0.032*	0.734 (0.549–1.291)	0.125
Extraprostatic extension	2.352 (1.399–4.569)	<0.001*	1.892 (0.897–3.219)	0.071
Positive margin	3.404 (1.778–6.091)	<0.001*	2.199 (0.782–3.988)	0.084
Seminal vesicle invasion	3.891 (1.584–5.822)	0.007*	1.329 (0.806–1.986)	0.322
Positive lymph node	2.012 (0.904–4.584)	0.091	1.212 (0.814–1.507)	0.532

CI: confidence interval; HR: hazard ratio; PSA: Prostate-specific antigen.
*Significant relationships of clinical factors with PSA progression-free survival.